| Date | Title | Description |
| 08.01.2022 | US-based biotech startup Ambagon Therapeutics raises USD 85 million in Series A round | Ambagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules, has raised USD 85 million in a Series A funding round led by Nextech Invest on 6 January 2022. |
| 07.01.2022 | Ambagon Therapeutics Raises $85M in Series A Funding | Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding.
The round was led by Nextech Invest with participation from RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ve... |
| 06.01.2022 | Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline | Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipel... |
